A 2024 IQVIA report on biosimilar competition in Europe highlights a dynamic market that is both shaped by competition and hindered by structural gaps, including absolute barriers to entry. The report indicates a significant surge in biological medicines losing market exclusivity is expected by the end of the decade.
This upcoming wave is projected to create an opportunity eight times greater than the 2012-2014 period, with a peak value of €30 billion between 2030 and 2032. This trend presents substantial opportunities for the life sciences industry and related service providers.
The report also calls for policymakers to evaluate reforms that could improve vaccine accessibility and uptake, particularly for older adults and high-risk individuals. This analysis from the IQVIA Institute provides critical market intelligence for stakeholders, including IQVIA itself, to navigate future industry developments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.